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The immune system’s quieter side went 
unnoticed for some time, while inflam-
mation-inducing proteins soaked up all 
the attention. Fiona Powrie stepped in 
just after the concept of inflammation-
reducing “suppressor” cells had emerged. 
In Don Mason’s laboratory at the MRC 
Cellular Immunology Unit in Oxford, 
Powrie and her colleagues lent the 
vaguely described cells definition, by 
showing that one set of CD4  +   T cells 
protected rats from death induced by 
injecting another set of T cells (1).
Two decades later, these protective 
regulatory T cells, now defined by expres-
sion of the transcription factor Foxp3, 
have stolen center stage. And Powrie 
has been watching them perform one 
of their most vital tasks: hushing in-
flammatory responses to food, as well as 
commensal and other nonthreatening 
microbes in the gut (2). She helped 
demonstrate that regulatory T cells in 
the intestines have the same qualities as 
those that quell inflam-
mation in response to 
self-antigens (3). In Bob 
Coffman’s laboratory at 
the DNAX Research 
Institute in California, 
she and her colleagues 
revealed that regulatory 
T cells act through the 
antiinflammatory cytok-
ines interleukin (IL)-10 and transform-
ing growth factor (TGF)- to counter 
inflammation driven by tumor necrosis 
factor (TNF)– and interferon (IFN)-–
producing effector T cells in mouse 
models of colitis (4, 5). As chair of the 
new Translational Gastroenterology 
Unit at the University of Oxford, Powrie 
will be working with clinicians to facili-
tate the application of what she knows 
about gut homeostasis to patients who’ve 
lost it.
Did your parents infl  uence your decision 
to become a scientist?
In a way, yes. But not from their own 
study. My father was in the fi  nancial 
world and my mother was a nurse. But 
my mother was very ill throughout my 
childhood with an immune-mediated 
disease. And that infl  uenced my interest 
in understanding the immune system 
and the devastating consequences that 
problems with that system could have.
Was there a particular moment when you 
thought, wow, regulatory T cells are cool?
I can remember a time when I was 
working on my PhD with Don Mason. 
We were trying to understand the 
functions of T cell subsets, and we dis-
covered that one subset of T cells led 
to a fatal disease in the animals and the 
other subset of T cells inhibited that 
disease. It was such a striking life-or-
death issue that it infl  uenced the rest 
of my career.
Why did you focus on the intestines?
The intestines are really the Wild West 
of the immune system. It’s the least 
understood part and it’s in close prox-
imity to a huge number of bacteria. 
There are actually more foreign cells in 
your body than your own cells, so the 
immune system must learn to live peace-
fully with this benefi  cial  commensal 
fl  ora. A breakdown of that relationship 
can cause disease.
BENCH TO BEDSIDE
At DNAX, were you constantly aware 
that the ultimate goal was a product?
Sure, DNAX was part of Schering-
Plough and the aim was to translate 
basic immunology research into new 
treatments for diseases. I was person-
ally involved with the development of 
recombinant IL-10 that moved into 
clinical trials. But in those days, 
DNAX still operated like a research 
institute and people pursued huge, 
fundamental questions related to the 
theme of immunology.
Do you still keep the pipeline in mind?
Absolutely. I think one of the things 
that DNAX did was give me exposure 
to how one might apply their work in 
the clinical setting. I think the transi-
tion from basic science into applied 
research is important. In fact, we are 
now developing a new Translational 
Gastroenterology Unit in Oxford in 
which laboratories for basic science 
research in model systems will sit right 
next to the Gastroenterology Clinic. 
It’s a fairly novel setup for translational 
medicine as I will head this new aca-
demic gastroenterology effort even 
though I’m not a clinician.
How do you see the basic and clinical 
research sides interacting?
This is a real challenge and has not always 
been successful in the past. A real issue 
is communication—both clinicians and 
scientists need to feel that they are a 
valued part of a team eff  ort. Having 
the basic laboratories so close to the 
clinic means that scientists and clini-
cians can talk to each other and share 
ideas. I mean, that’s what makes science 
so fun, really. If you didn’t tell people 
what you did, what would be the point 
of doing it?
I think people will communicate 
though. I work with a fabulous set of cli-
nicians who are very willing to listen to 
what’s coming out of the basic science 
research and think about how we can 
apply it to the clinical setting. Now we’ll 
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be able to take the pathways that we’ve 
identified in model systems and actu-
ally ask if this is what we see in inflam-
matory bowel disease patients. For 
example, we would like to identify 
subsets of patients that might be more 
suited for one treatment versus an-
other, rather than applying a treatment 
across the board.
What went wrong in the immunomod-
ulatory drug trial that tested the CD28 
superagonist antibody TGN-1412?
Well, there were unanticipated results in 
humans that were not obvious from the 
studies that had been performed in pri-
mates. It turned out to be a more potent 
stimulus than expected and the eff  ects 
were profound. Of course, the trial has 
led to a lot of caution in terms of inject-
ing things that we would consider to be 
agonistic or activating antibodies. And it 
made us aware that when you cross spe-
cies, it’s not always possible to predict 
function because of diff  erent receptors 
and so on. One has to be extremely cau-
tious when moving experimental treat-
ments into humans. At the same time we 
do need to move forward with novel 
therapies. It’s a balance.
What do you predict about the next wave 
of immunomodulatory drugs?
Anti-TNF treatments already work 
fabulously in some patients with in-
fl  ammatory diseases. But some patients 
don’t respond. I think one of the ideas 
that has emerged from our work and 
others is that it may not be suffi   cient 
to simply take away infl   ammatory 
drivers; you need to reset the balance. 
And that’s where regulatory pathways 
are important. I think we will advance 
the fi  eld by learning how to manipu-
late these populations of cells. It’s hard 
to think that cell-based therapies will 
be widely acceptable in terms of their 
costs. But there should be ways to ad-
minister agents that promote regula-
tory T cell responses in situ. This could 
be useful for inhibiting autoimmune 
and infl  ammatory disease, allergy, and 
graft rejection.
CHEWABLE TREATMENTS
Does our diet aff  ect intestinal infl  ammation?
Diet absolutely plays into it. I mean, one 
of the treatments for infl  ammatory bow-
el disease is changing your diet. There 
are certain foods that potentially infl  u-
ence the intestinal bacteria. And we 
know that components of our diet have 
a very important role in infl  uencing 
immune function. But pinning down 
defi   nitive molecules and pathways is 
challenging. Still, there has been some 
progress. There’s a lot of interest in the 
eff  ect that vitamin A has on infl  uencing 
immune function at the moment. Also, 
when researchers have knocked out 
short chain fatty acid receptors in mice, 
they’ve shown that it infl  uences intes-
tinal homeostasis.
What do you think about the probiotics 
industry?
I think it’s an interesting area. There is 
evidence that for retaining remission 
in infl  ammatory bowel disease, probi-
otics can help. However, the data about 
whether probiotics can treat a fl   are 
isn’t as convincing. Precisely how pro-
biotics, or prebiotics, are working and 
what immune cells they interface with 
is not understood. I do think it’s an 
important area for the food industry to 
explore, so that one can design nutri-
tional components that are enhanced 
over the ones we have. I mean, you can 
put things into the gut. That’s so much 
easier than getting something into 
joints or into the brain. So this is an 
area that we can easily manipulate, but 
we need to understand more about it. 
One approach is to administer bacteria 
that produce molecules that restore 
immune homeostasis. This concept is 
being used in Phase III clinical trials 
now, with a probiotic bacteria that can 
deliver an antiinfl  ammatory type cy-
tokine called IL-10. By ingesting this 
probiotic bacteria, you can deliver, in a 
targeted fashion, something that is 
good for intestinal homeostasis. These 
bacteria are equipped with suicide 
genes so that the organisms don’t become 
a potential hazard.
If you switched your focus, what would 
you turn to?
If I had to do it again, I might look into 
inherited immune diseases. For example, 
I’d look at individuals who are suscepti-
ble to bacterial infections that run in the 
family. Investigators have been able to 
actually go in and identify the pathways 
that are altered. And that 
has provided a lot of 
insight into immunity 
and  host-susceptibility. 
Another fascinating area 
is understanding how 
tissues shape the immune 
response. If we’re going 
to develop therapies for 
diseases, we want to be 
able to target that action 
to particular organs, and 
understanding the inter-
action between the stroma of an organ 
and immune cells may provide novel 
pathways for organ-specifi  c targeting in 
various diseases. There are lots of things 
I’d do … and actually, I might yet.
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Foxp3  +   (red) and CD4  +   (green) regulatory 
T cells inhabit the spleen.
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